Repotrectinib, a targeted drug for ROS1-positive non-small cell lung cancer, provides relief, but its potential side effects require timely detection and scientific management.
I. Common Side Effects and Incidence of Repotrectinib
1. Nervous System Reactions
(1) Dizziness (64%), gait incoordination (29%), cognitive impairment (23%), etc.
(2) In severe cases, mood swings (6%) or sleep problems (15%) may occur.
2. Digestive System and Systemic Reactions
(1) Abnormal taste (50%), constipation (37%), nausea (20%).
(2) Fatigue (29%), muscle weakness (21%), weight gain (14%).
3. Abnormal Laboratory Indicators
Elevated creatine phosphokinase (57%), abnormal liver function (ALT elevated 35%, AST elevated 40%), etc.
II. Remedies and Management of Repotrectinib Side Effects
1. Management of Neurological Reactions
(1) Avoid driving and operating machinery if dizziness or balance disorders occur.
(2) Discontinue medication for moderate to severe symptoms. Resume medication at the same or reduced dose after symptoms subside.
2. Monitoring and Management of Hepatotoxicity
(1) Monitor liver function every 2 weeks before and during the initial stage of treatment, and repeat monthly thereafter.
(2) Permanently discontinue medication if liver function is significantly abnormal.
3. Management of Muscle Symptoms and Hyperuricemia
(1) Monitor creatine phosphokinase levels for unexplained muscle pain.
(2) Patients with hyperuricemia should use uric acid-lowering drugs according to clinical indications.
4. Risk of Fractures and Warning Signs of Pulmonary Symptoms
(1) Report bone pain or limited mobility symptoms promptly.
(2) Seek immediate medical attention for new or worsening cough or dyspnea to rule out interstitial lung disease.
III. Drug Interactions and Contraindications of Repotrectinib
1. Contraindicated Drug Use
(1) Potent or intermediate-potency CYP3A inhibitors and inducers.
(2) Avoid using hormonal contraceptives; effective non-hormonal contraceptive methods are recommended.
IV. Proper Storage and Environmental Requirements for Repotrectinib
1. Storage Conditions
Store at room temperature (20°C–25°C, 68°F–77°F). Short-term storage at 15°C–30°C is permissible.
2. Precautions for Use
(1) Swallow the capsule whole. Do not open, chew, or crush the capsule.
(2) Do not take if the capsule is broken.
(3) If a dose is missed or vomited after taking the medication, no additional dose is needed; take the next dose at the scheduled time.
V. Special Population Warnings for Repotrectinib
1. Pregnant and Lactating Women
(1) Use of this medication in pregnant women may cause fetal malformations. Effective non-hormonal contraception should be used during treatment and for two months after the last dose.
(2) Lactating patients should discontinue breastfeeding during treatment and for 10 days after the last dose.
